Why Adimarket Offers Both PRP Equipment and Marketing Services

TUESDAY, 23 JANUARY 2018 / PUBLISHED IN BLOG

Here at Adimarket, we sell equipment to practices that are willing and able to add PRP and stem cell therapies to their lineup. The equipment we offer is among the best, and we have helped hundreds of doctors and practices to offer PRP and stem cell therapies. However, we also provide marketing services above that as well.

The Importance of Marketing in Regenerative Medicine

Although it might seem odd that we offer both marketing services and equipment, it is not so odd once you understand why. Simply offering services and having the equipment to do so does not in itself help patients to fully know that you are offering new services. It is best practice to get the word out to as many people in the area as possible.

Why Marketing Services are Essential

While there are many reasons why we do this, here are the three main reasons:

1. Regenerative Medicine is Relatively New

Compared to many other medical practices, such as surgery and physical therapy, regenerative medicine is still fairly new. In fact, most people do not really know that PRP and stem cell therapy even exists, let alone can be used to manage chronic pain.

The fact that not many people even know about the existence of regenerative medicine, let alone what it can be used for, means that it would be difficult to get your patients to even understand what you are offering as a service. This can be addressed with marketing. Through marketing, a practice can not only let it become known that they are offering these new services, but also explain shortly what the service entails.

2. Marketing is Like Dieting

Pretty much every doctor and dietitian knows that good nutrition is vital to great health down the line. Waiting until you’re sick and deficient to discuss nutrition is not the best way to address the issue. Marketing is similar in that instance. Marketing not only can be used to keep current patients informed, but can also be used to inform new patients about what you offer. Practices that don’t market often suffer in the same way as people who don’t get good nutrition.

3. There’s a Lot of Competition

Medicine has sadly become more and more like a business in recent years. This means that even doctors and practices need to have a good business sense if they are going to continue to provide the type of services that patients need and desire. Not understanding business would only make any practice fail or at least prevent them from growing.

Because of this, private practices, as well as other medical groups, are forced to compete. Marketing is a big way to make sure that you get patients instead of your competition. If you are utilizing PRP and stem cell therapies as a way to generate more income, then great! However, you will still have to market those services to get the word out, as well as compete.

How Adimarket Supports Your Practice

We at Adimarket offer these services as a way to help the field of regenerative medicine succeed. We not only help your practice start to utilize regenerative medicine, but we also help you to promote your practice in the same way. This will help your patients know that you are using these methods, and what they are, so that you can get a leg up over the competition.

Introduction

The International Federation of Adipose Therapeutics and Sciences (IFATS) appreciates this opportunity to submit the following comments to supplement its earlier written comments and recent testimony at the September 12-13, 2016 Public Hearing on the 2014-2015 Draft HCT/P Guidances concerning: a) Minimal Manipulation; b) Same Surgical Procedure; c) Adipose Tissue; and d) Homologous Use.

IFATS Overview

International Federation of Adipose Therapeutics and Sciences (IFATS)
45 Lyme Road – Suite 304
Hanover, NH 03755 USA
Tel: 1-603-643-2325, Fax: 1-603-643-1444

Date: September 26, 2016

Addressed to:
Division of Dockets Management (HFA–305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

Re: FDA-2014-D-1856 – Comments to 2014-2015 Draft Guidance regarding:

• Docket FDA-2014-D-1584: “Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception; Draft Guidance for Industry”
• Docket FDA-2014-D-1696: “Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidance for Industry and Food and Drug Administration Staff”
• Docket FDA-2014-D-1856: “Human Cells, Tissues, and Cellular and Tissue-Based Products from Adipose Tissue: Regulatory Considerations; Draft Guidance for Industry”
• Docket FDA-2015-D-3581: “Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidance for Industry and FDA Staff”

Commitment to Advancing Adipose-Based Therapies

IFATS is committed to the responsible advancement of the science and translation of new adipose therapies, ensuring patient safety. Founded in 2003 by pioneering adipose stem cell biologists and clinician–scientists, IFATS aims to advance the science of adipose tissue biology and its clinical translation to therapeutic applications.

IFATS’s Global Influence and Expertise

Membership now spans 40 countries across North America, Europe, Africa, the Middle East, Asia, Australia, and Central and South America. It includes basic scientists, translational researchers, clinicians, and regulatory and biotech representatives. IFATS is aligned with prestigious journals, Stem Cells and Stem Cells Translational Medicine, and has contributed to defining adipose-derived cells in the publication Cytotherapy.

Review of FDA Draft Guidances

Drawing on this expertise, IFATS has reviewed the 4 draft guidances with great care. It respectfully requests the FDA to reconsider and modify the 4 draft HCT/P guidances as follows:

Recommendations

Recommendation #1: Cell-Based Risks

Interpret and evaluate an HCT/P’s homologous use and minimal manipulation based on its manufacturer’s intended use in the patient.

Recommendation #2: Provider-Based Risks

Reduce provider-created risks by targeting provider behavior.

Recommendation #3: Recognize Structural and Nonstructural Functions

Recognize that adipose HCT/Ps have both structural and nonstructural functions, and regulate based on its manufacturer’s intended use in the patient.

Recommendation #4: Revise Evaluation of Minimal Manipulation and Homologous Use

Revise the evaluation of minimal manipulation and homologous use as they pertain to particular applications of adipose tissue.

Conclusion

IFATS is committed to collaborating with the FDA to meet the challenges of regulating HCT/P therapies. We respectfully request a meeting with FDA representatives to discuss these issues and others related to the advancement and regulation of adipose-based therapies.

Respectfully submitted on behalf of IFATS,

Adam J. Katz, MD, FACS
Chair, IFATS Regulatory Affairs Committee & IFATS Co-Founder
University of Florida College of Medicine
Professor
Director of Plastic Surgery Research, Laboratory of BioInnovation and Translational Therapeutics
Division of Plastic Surgery, Department of Surgery

IFATS Board of Directors

• Bruce Bunnell, PhD – Tulane University / United States
• Louis Casteilla, PhD – University of Toulouse / France
• Sydney Coleman, MD – New York & Pittsburgh Universities / United States
• Julie Fradette, PhD – Lavalle University / Canada
• William Futrell, MD – Founders’ Board, University of Pittsburgh / United States
• Marco Helder, PhD – VU University Medical Center Amsterdam / The Netherlands
• Adam J. Katz, MD, FACS – Founders’ Board, University of Florida / United States
• Ramon Llull, MD, PhD – Founders’ Board, University of Barcelona / Spain
• Kacey Marra, PhD – University of Pittsburgh / United States
• Ricardo Rodriguez, MD – President (2016), Private Practice / Johns Hopkins / United States
• Peter Rubin, MD, FACS – Chair, Founders’ Board, Chairman of the Board, University of Pittsburgh / United States
• Stuart K. Williams, PhD – University of Louisville / United States

Members-at-Large

• Jeff Gimble, MD, PhD – Pennington Biomedical / United States
• Keith March, MD, PhD – Indiana University / United States

IFATS Recommendations for FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products

Introduction

IFATS recognizes the FDA’s challenge in developing regulations that fulfill the agency’s dual and interrelated responsibilities of protecting patients while promoting innovation. Although these are complementary rather than competing objectives, they are often difficult to pursue simultaneously. The FDA’s 3-tiered, risk-based §§ 361 – 351 framework balances these concerns by making the degree of regulatory oversight proportionate to the degree of an HCT/P therapy’s risk.

Key Regulatory Concepts

The concepts of homologous use and minimal manipulation are key determinants of whether an HCT/P will be classified as a § 361 product (which does not need premarket approval) or a § 351 drug, device, and/or biological product (which requires formal premarket approval). The applicability of § 351’s “same surgical procedure” exception also turns on homologous use and minimal manipulation.

Challenges for Manufacturer-Clinicians

For most manufacturer-clinicians, § 351 categorization raises insurmountable obstacles due to the time and expense of obtaining premarket approval. In such cases, § 351 classification effectively prohibits access to safe and effective HCT/P therapies, even when those therapies involve a patient’s own cells and/or can deliver superior results with reduced risks. At the same time, § 351 oversight is essential for therapies that pose greater risks due to the HCT/P’s characteristics, mechanism(s) of action, and circumstances of use.

Addressing Provider Misconduct

A second type of risk involves rogue clinicians offering false promises in the form of unproven therapies performed with few safeguards and less training. Provider misconduct is not unique to HCT/P therapies; it pervades all areas of medical practice. Nevertheless, IFATS shares the FDA’s alarm over such practices in the context of HCT/Ps and is equally determined to curtail them. Effective regulation of HCT/P-related risks must recognize and respond to their multivariate causes. Put simply:

• Sections 351 and 361 appropriately attempt to regulate HCT/P therapies proportionate to the risks of unpredictable and/or unsafe cell behavior.
• However, the risks of untrained providers misusing HCT/P therapies are caused by providers misbehaving, not cells misbehaving.

Comprehensive Risk Management Strategy

Interpretive guidance that restricts the definition and application of HCT/P terminology can only go so far in restricting provider-based risks. Additionally, restrictive, inaccurate, or imprecise definitions and interpretations carry their own risks of restricting access to therapies and a patient’s right to evaluate risk through the process of informed consent. Therefore, IFATS recommends that the FDA adopt an overall two-part strategy that focuses on both categories of HCT/P risks: those relating to cell behavior and those that pertain to provider behavior.

Recommendations

Recommendation #1 – Cell-Based Risks

Interpret and evaluate an HCT/P’s homologous use and minimal manipulation based on its manufacturer’s intended use in the patient. Interpretive guidance should predicate each definition on the functions and/or characteristics of the specific composition (i.e., cell type(s) and/or matrix or other component(s)) that are involved in, and/or relevant to, the manufacturer-clinician’s intended use in the patient.

Recommendation #2 – Provider-Based Risks

To reduce provider-created risks, the FDA should target provider behavior by collaborating with IFATS and comparable organizations to draw on and supplement existing federal and state methods of certification, registration, and similar measures.

Detailed Explanation of Recommendations

Recommendation #1 – Cell-Based Risks

The four draft guidances on homologous use, minimal manipulation, same surgical procedure, and adipose tissue individually and collectively intend to “improve stakeholders’ understanding” of 21 CFR 1271 by clarifying the FDA’s interpretation of homologous use and minimal manipulation. As demonstrated by the initial round of public comments and the ensuing public hearing on September 12 and 13, 2016, the draft guidance documents have not clarified applicable regulations. They have instead compounded the difficulty of understanding and complying with them. The drafts’ introduction of new definitional inaccuracies has also amplified rather than reduced patient risk.

IFATS respectfully requests the agency to clarify the definitions and application of homologous use and minimal manipulation by interpreting each as referring to the characteristics of the specific cell type(s) and/or the matrix or other component(s) that are involved in, and/or relevant to, the manufacturer’s intended use in the patient.

Homologous Use Definition:

21 CFR 1271.3(c): Homologous use means the repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.

Recommended Guidance:

As used in this section, “performs the same basic function or functions in the recipient as in the donor” shall be interpreted as referring to one or more of the functions of the specific composition of the therapeutic/product, reflecting the specific cell type(s) and/or the specific matrix or other component(s) in the donor tissue that are involved in, and/or relevant to, the manufacturer’s intended use in the patient.

Minimal Manipulation Definition:

21 CFR 1271.3(f) Minimal manipulation means:

• For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement;
• For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells.

Recommended Guidance:

As used in this section, “relevant” characteristics shall be interpreted to mean the characteristics of the specific cell type(s) and/or the specific matrix or other component(s) in the donor tissue that are involved in, and/or relevant to, the manufacturer’s intended use in the patient.

Rationale:

Incorporating and relying on the manufacturer’s intended use harmonizes the interpretation and definition of homologous use and minimal manipulation with statutory directives to predicate the regulation of drugs, devices, and biologics on the manufacturer’s intended use. Defining relevant characteristics in terms of “the characteristics of specific cell type(s) and/or the matrix or other component(s) in the donor tissue that are involved in, and/or relevant to the manufacturer’s intended use in the patient” promotes patient safety by insisting on a reasonable and scientifically supportable rationale for using an HCT/P for a particular mechanism of action. This clarification balances the FDA’s dual responsibilities of protecting patients from undue safety risks while promoting the ongoing availability and continued development of HCT/P therapies.

Example of Non-Homologous Use:

Decellularized adipose matrix used to accomplish the manufacturer’s intended use of a particular metabolic or systemic effect in the patient (e.g., reducing insulin levels in a diabetic patient) is non-homologous because decellularized matrix is not relevant to metabolic or systemic activity.

Conclusion

Adopting this two-part strategy can control risk more comprehensively—and therefore more effectively—in furtherance of the FDA’s dual and interrelated obligations of protecting patients and promoting the availability of HCT/P therapies.

Introduction to FDA Regulations and IFATS Recognition

IFATS acknowledges the FDA’s dual role in patient protection and innovation promotion within the HCT/P sector. Balancing these objectives is crucial yet challenging.

Understanding the FDA’s Risk-Based Framework

The FDA’s § 361 – § 351 framework categorizes HCT/P therapies based on risk levels, influenced by concepts like homologous use and minimal manipulation.

Impact of Regulatory Classification on Access to HCT/P Therapies

Homologous use and minimal manipulation determine whether an HCT/P falls under § 361 (no premarket approval needed) or § 351 (requires premarket approval), affecting accessibility and innovation.

Provider Misconduct Risks in HCT/P Therapies

Rogue clinicians offering unproven therapies pose significant risks. Addressing provider behavior is essential for patient safety and regulatory efficacy.

IFATS Recommendations for Risk Mitigation

Recommendation #1 – Cell-Based Risks: Interpreting Homologous Use and Minimal Manipulation

IFATS proposes clarifying homologous use and minimal manipulation definitions based on manufacturer-intended use, enhancing regulatory clarity and patient safety.

Recommendation #2 – Provider-Based Risks: Targeting Provider Behavior

Collaboration with IFATS and other bodies to enhance certification and monitoring mechanisms can mitigate risks associated with provider misconduct effectively.

Recommendation #3 – Regulatory Scope for Adipose HCT/Ps

Expanding the definition of adipose tissue to include both structural and nonstructural functions aligns with biological accuracy and regulatory intent.

Conclusion: Enhancing Patient Safety and Access to HCT/P Therapies

IFATS urges the FDA to adopt a comprehensive strategy that addresses both cell-based and provider-based risks to uphold patient safety and foster innovation in HCT/P therapies.

Regulating an HCT/P’s Risks Based on Manufacturer’s Intended Use

Regulating the risks of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) is crucially tied to their intended use and mechanisms of action in patients. This ensures effective regulatory oversight and evaluation.

Regulatory Framework: §§ 351-361

The regulatory oversight of HCT/Ps under §§ 351-361 hinges on assessing the product’s risk level. Central to this determination are the criteria of homologous use and minimal manipulation.

Homologous Use Defined (21 CFR 1271.3(c))

Homologous use is defined as the repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function as in the donor.

Minimal Manipulation Criteria (21 CFR 1271.3(f))

Minimal manipulation of structural tissue involves processing that preserves the tissue’s original characteristics essential for its utility in repair, reconstruction, or replacement. For nonstructural tissues, it preserves relevant biological characteristics.

Impact on Adipose Tissue

The classification of adipose tissue as exclusively structural neglects its nonstructural functions, limiting evaluation under § 361 criteria and obstructing risk assessment.

Same Surgical Procedure Exception

The § 351 “same surgical procedure” exception applies only to HCT/Ps meeting homologous use and minimal manipulation criteria, impacting nonstructural adipose applications.

Recommendation #4: Revising Evaluation Criteria

IFATS urges the FDA to reconsider specific adipose tissue applications concerning homologous use and minimal manipulation criteria.

Example A: Decellularizing Adipose Tissue

Decellularization of adipose tissue for structural use should be recognized as minimal manipulation under §§ 351 and 361 guidelines.

Example B: Structural Use of Fat in Breast Surgery

Applying adipose tissue for breast augmentation should be considered homologous use due to its structural function in restoring form and shape.

Example C: Stromal Vascular Fraction (SVF) for Nonstructural Use

SVF extraction from adipose tissue retains nonstructural components crucial for nonstructural applications, meeting minimal manipulation and homologous use criteria.

Conclusion and Call to Action

IFATS requests the FDA to amend draft guidance on HCT/Ps to align with scientific understanding and clinical practices of adipose tissue applications.

References
 

1. Bourin P, Bunnell  BA,  Casteilla  L,  Dominici  M,  Katz  AJ,  March  KL,  Redl  H,  Rubin  JP, Yoshimura K, Gimble Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15:641-648
2. Diaz-Flores L, Gutierrez R, Madrid JF, Varela H, Valladares F, Acosta E, Martin-Vasallo P, Diaz-Flores L, Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol. 2009;24:909-969
3. Gimble The function of adipocytes in the bone marrow stroma. The New Biologist. 1990;2:304-312
4. Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell B, Broome Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin  during   caloric   restriction.   Cell   metabolism. 2014;20:368-375
5. Meunier P, Aaron J, Edouard C, VlGNON Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: A quantitative study of 84 iliac bone biopsies. Clinical orthopaedics and related research. 1971;80:147-154
6. N. Über die wiederanheilung vollstädig vom körper getrennter, die ganze fettschicht en- thaltender hautstucke. Zbl f Chir 1893;30:16-17
7. Hollander E, Joseph Cosmetic surgery. Handbuch der  Kosmetik.  Leipzig,  Germany: Veriag von Velt. 1912;688
8. Miller Cannula implants and review of implantation technics in esthetic surgery: In two parts. Oak Press; 1926.
9. Gimble JM Fat circadian biology. Journal of applied physiology. 2009;107:1629-1637
10. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds Identification and expression cloning of a leptin receptor, ob-r. Cell. 1995;83:1263-1271
11. Salgado AJ,  Gimble    Secretome  of  mesenchymal  stem/stromal  cells  in  regenerative  medicine.

Biochimie. 2013;95:2195

12. Salgado AJ, Reis RL, Sousa N, Gimble Adipose tissue derived stem cells secretome: Soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther. 2009
13. Khan M, Joseph Adipose tissue and adipokines: The association with and application of adipokines in obesity. Scientifica. 2014;2014
14. Vicennati V, Garelli S, Rinaldi E, Di Dalmazi G, Pagotto U, Pasquali Cross-talk between

adipose tissue and the hpa axis in obesity and overt hypercortisolemic states. Hormone molecular biology and clinical investigation. 2014;17:63-77

15. Kargi AY, Iacobellis Adipose tissue  and  adrenal  glands:  Novel  pathophysiological mechanisms and clinical applications. International journal of endocrinology. 2014;2014
16. Maïmoun L, Georgopoulos NA, Sultan Endocrine disorders in adolescent and young female athletes: Impact on growth, menstrual cycles, and bone mass acquisition. The Journal of Clinical Endocrinology

& Metabolism. 2014;99:4037-4050

17. McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, Kloster A, Di Halvorsen Y, Ting JP,

Storms RW. The immunogenicity of human adipose‐derived cells: Temporal changes in vitro. Stem cells. 2006;24:1246-1253

18. McIntosh KR,  Frazier  T,  Rowan  BG,  Gimble    Evolution  and  future   prospects   of adipose- derived immunomodulatory cell therapeutics. Expert review of clinical immunology. 2013;9:175-184
19. McIntosh KR,   Lopez   MJ,  Borneman  JN,  Spencer  ND,  Anderson  PA,   Gimble    Immunogenicity of allogeneic adipose-derived stem cells in a rat spinal fusion model. Tissue Engineering Part A. 2009;15:2677-2686
20. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, Di Halvorsen Y, Storms RW, Goh B, Kilroy G. Immunophenotype of human adipose‐derived cells: Temporal changes    in      stromal‐associated and  stem   cell–associated    markers.   Stem   cells. 2006;24:376-385

21. Gimble JM, Dorheim MA, Cheng Q, Medina K, Wang CS, Jones R, Koren E, Pietrangeli C, Kincade Adipogenesis in a murine bone marrow stromal cell line capable of supporting b lineage lymphocyte growth and proliferation: Biochemical and molecular characterization. European journal of immunology. 1990;20:379-387
22. Frazier TP, McLachlan JB, Gimble JM, Tucker HA, Rowan Human adipose-derived stromal/stem cells induce functional cd4+ cd25+ foxp3+ cd127− regulatory t cells under low oxygen culture conditions.  Stem cells and development. 2014;23:968-977

23. Frazier TP, Gimble JM, Kheterpal I, Rowan Impact of low oxygen on the secretome of human adipose- derived stromal/stem cell primary cultures. Biochimie. 2013;95:2286-2296
24. Miranville A, Heeschen C, Sengenes C, Curat C, Busse R, Bouloumie Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004;110:349-355
25. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ,  Bovenkerk  JE,  Pell  CL, Johnstone BH, Considine RV, March Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109:1292-1298
26. Planat-Benard V, Silvestre J-S, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez Plasticity of human adipose lineage cells toward endothelial cells physiological  and   therapeutic   perspectives.   Circulation. 2004;109:656-663
27. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble  Cytokine  profile  of human  adipose-derived stem cells: Expression of angiogenic, hematopoietic, and pro- inflammatory factors. J Cell Physiol. 2007;212:702-709
28. Ribeiro CA, Fraga JS, Grãos M, Neves NM, Reis RL, Gimble JM, Sousa N, Salgado The secretome of  stem  cells  isolated  from  the  adipose  tissue  and  wharton  jelly  acts differently  on central nervous  system  derived  cell populations.  Stem Cell  Res  Ther. 2012;3:18
29. Silva NA, Gimble JM, Sousa N, Reis RL, Salgado Combining adult stem cells and olfactory ensheathing cells:   The   secretome  effect.   Stem   cells   and   development. 2013;22:1232-1240
30. Cho YJ, Song  HS,  Bhang  S,  Lee S,  Kang  BG,  Lee  JC,  An  J,  Cha  CI,  Nam DH,  Kim. Therapeutic effects of human adipose stem cell‐conditioned medium on stroke. Journal of neuroscience research. 2012;90:1794-1802

31. Egashira Y, Sugitani S, Suzuki Y, Mishiro K,  Tsuruma  K,  Shimazawa  M,  Yoshimura  S, Iwama T, Hara The conditioned medium of murine and human adipose-derived stem cells exerts neuroprotective effects against experimental stroke model. Brain research. 2012;1461:87-95
32. Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel Ifats collection:The conditioned media of adipose stromal cells protect against hypoxia‐ischemia‐induced brain damage in neonatal rats. Stem Cells. 2009;27:478-488

33. Wei X, Zhao L, Zhong J, Gu H, Feng D, Johnstone B, March K, Farlow M, Du Adipose stromal cells-secreted neuroprotective media against neuronal apoptosis. Neuroscience letters. 2009;462:76-79
34. Zhao L, Wei X, Ma Z, Feng D, Tu P, Johnstone B, March K, Du Adipose stromal cells- conditional  medium  protected   glutamate-induced   cgns   neuronal  death   by  bdnf. Neuroscience letters. 2009;452:238-240
35. Cousin B, André M, Arnaud E, Pénicaud L, Casteilla Reconstitution of lethally irradiated mice by cells isolated from adipose tissue. Biochemical and biophysical research communications. 2003;301:1016-1022
36. Han J, Koh YJ, Moon HR, Ryoo HG,  Cho  CH,  Kim  I,  Koh    Adipose  tissue  is  an extramedullary reservoir for functional hematopoietic stem and progenitor cells. Blood.2009
37. Harms M, Seale Brown and beige fat: Development, function and therapeutic potential. Nature medicine. 2013;19:1252-1263
38. Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, Lecka-Czernik Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology. 2013;154:2687-2701

39. Wu J, Cohen P, Spiegelman Adaptive thermogenesis in adipocytes: Is beige the new brown? Genes & development. 2013;27:234-250
40. Krings A, Rahman S, Huang S, Lu Y, Czernik P, Lecka-Czernik Bone  marrow  fat  has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone. 2012;50:546-552
41. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500-1508
42. Peirce V, Carobbio S, Vidal-Puig The different shades of fat. Nature. 2014;510:76-83
43. Enerbäck S, Gimble Lipoprotein lipase gene expression: Physiological regulators at the transcriptional and post-transcriptional level. Biochimica et Biophysica Acta (BBA)- Lipids and Lipid Metabolism. 1993;1169:107-125
44. Rudolph MC, Neville MC, Anderson Lipid synthesis in  lactation: Diet  and  the fatty acid switch. Journal of mammary gland biology and neoplasia. 2007;12:269-281
45. Gimble JM, Katz AJ, Bunnell Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100:1249-1260

46. Bellows CF, Zhang Y, Chen J, Frazier ML, Kolonin Circulation of progenitor cells in obese  and lean   colorectal   cancer   patients.   Cancer   Epidemiology   Biomarkers   & Prevention. 2011;20:2461- 2468
47. Bellows CF, Zhang Y, Simmons PJ, Khalsa AS, Kolonin Influence of bmi on level of circulating progenitor cells. Obesity. 2011;19:1722-1726
48. Krijnen PA NB, Meinster E, Vo K, Musters RJ, Kamp O, Niessen HW,, Juffermans LJ. Acute myocardial infarction does not affect functional characteristics of adipose derived stem cells in rats, but reduces the number of stem cells in adipose tissue. IFATS Annual Meeting. 2014:100
49. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH,March KL. A population of multipotent cd34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circulation research. 2008;102:77-85

50. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, Murphy M, Johnstone BH, Ingram DA, March Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circulation research. 2009;104:1410-1420
51. Merfeld-Clauss S, Gollahalli N, March KL, Traktuev Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Tissue Engineering Part A. 2010;16:2953-2966
52. Merfeld-Clauss S, Lupov IP, Lu H, Feng D, Compton-Craig P, March KL, Traktuev.  Adipose stromal cells differentiate along a smooth muscle lineage pathway upon endothelial cell contact via induction of activin a. Circulation research. 2014;115:800-809

53. Crisan M, Yap S, Casteilla L, Chen C-W, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang A perivascular origin for mesenchymal stem cells in multiple human organs. Cell stem cell. 2008;3:301-313
54. Ter Horst E, Naaijkens B, Krijnen P, Van Der Laan A, Piek J, Niessen Induction of a monocyte/macrophage phenotype switch by mesenchymal stem cells might contribute to improved infarct healing postacute myocardial infarction. Minerva cardioangiologica. 2013;61:617-625
55. Guisantes E,  Fontdevila  J,  Rodríguez    Autologous  fat   grafting   for   correction  of unaesthetic scars. Annals of plastic surgery. 2012;69:550-554
56. Klinger M, Caviggioli F, Klinger FM, Giannasi S, Bandi V, Banzatti B, Forcellini D, Maione L, Catania B, Vinci Autologous fat graft in scar treatment. Journal of Craniofacial Surgery. 2013;24:1610-1615
57. Klinger M, Marazzi M, Vigo D, Torre Fat injection for cases of severe burn outcomes: A new perspective of  scar  remodeling  and   reduction.   Aesthetic  plastic   surgery. 2008;32:465-469
58. Khouri RK, Smit JM, Cardoso E, Pallua N, Lantieri L, Mathijssen IM, Khouri Jr RK, Rigotti Percutaneous aponeurotomy and lipofilling: A regenerative alternative to flap reconstruction? Plastic and reconstructive surgery. 2013;132:1280-1290
59. Balkin DM, Samra S, Steinbacher Immediate fat grafting in primary cleft lip repair. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2014;67:1644-1650
60. Rigotti G,  Marchi  A,  Galie  M,  Baroni  G,  Benati  D,  Krampera  M,  Pasini  A, Sbarbati.  Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: A healing process  mediated by  adipose-derived  adult  stem  cells.  Plastic  and  reconstructive surgery. 2007;119:1409-1422

61. Villani F, Caviggioli F, Klinger F, Klinger Rehabilitation of irradiated head and neck tissues by autologous  fat   transplantation.   Plastic   and   reconstructive   surgery. 2009;124:2190-2191
62. Chang CC,  Thanik  VD,  Lerman  OZ,  Saadeh  PB,  Warren  SM,  Coleman  SR,  Hazen   Treatment   of   radiation   skin   damage   with   coleman   fat   grafting.   STEM   CELLS. 2007;25:3280-3281
63. Sultan SM, Stern CS, Allen Jr RJ, Thanik VD, Chang CC, Nguyen PD, Canizares O, Szpalski C, Saadeh PB, Warren Human fat grafting alleviates radiation skin damage in a murine model. Plastic and reconstructive surgery. 2011;128:363-372
64. Loder S, Peterson JR, Agarwal S, Eboda O, Brownley C, DeLaRosa  S,  Ranganathan  K, Cederna P, Wang SC, Levi Wound healing after thermal injury is improved by fat and adipose-derived stem cell isografts. Journal of Burn Care & Research. 2015;36:70-76

65. Sultan SM, Barr JS, Butala P, Davidson EH, Weinstein AL, Knobel D, Saadeh PB, Warren SM, Coleman SR, Hazen Fat grafting accelerates revascularisation and decreases fibrosis following thermal injury. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2012;65:219-227
66. Cuomo R, Zerini I, Botteri G, Barberi L, Nisi G, D’ANIELLO Postsurgical pain related to breast implant: Reduction with lipofilling procedure. In Vivo. 2014;28:993-996
67. Maione L,  Vinci  V,  Caviggioli  F,  Klinger  F,  Banzatti  B,  Catania  B,  Lisa  A,  Klinger   Autologous fat graft in postmastectomy pain syndrome following breast conservative surgery and radiotherapy. Aesthetic plastic surgery. 2014;38:528-532
68. Caviggioli F,  Maione  L,  Forcellini D,  Klinger  F,  Klinger    Autologous  fat   graft   in postmastectomy pain syndrome. Plastic and reconstructive surgery. 2011;128:349-352
69. Caviggioli F, Vinci V, Codolini Autologous fat grafting: An innovative solution for the treatment of post-mastectomy pain syndrome. Breast Cancer. 2013;20:281-282
70. Salgarello M, Visconti The role of sacrolumbar fat grafting in the treatment of spinal fusion instrumentation-related chronic  low  back  pain:  A  preliminary  report.  Spine. 2014;39:E360-E362
71. Faroni A, Terenghi G, Reid Adipose-derived stem cells and nerve regeneration: Promises and pitfalls. Int Rev Neurobiol. 2013;108:121-136
72. Vaienti L, Gazzola R, Villani F, Parodi Perineural fat grafting in the treatment of painful neuromas. Techniques in hand & upper extremity surgery. 2012;16:52-55
73. Marangi GF, Pallara T, Cagli B, Schena E, Giurazza F, Faiella E, Zobel BB, Persichetti Treatment of  early-stage  pressure  ulcers  by  using  autologous  adipose  tissue  grafts. Plastic Surgery International. 2014;2014
74. Lolli P, Malleo G, Rigotti Treatment of chronic anal fissures and associated stenosis by autologous adipose tissue transplant: A pilot study. Diseases of the Colon & Rectum. 2010;53:460-466
75. Cantarella G,  Baracca  G,  Forti  S,  Gaffuri  M,  Mazzola    Outcomes  of  structural  fat grafting for paralytic and non-paralytic dysphonia. Acta Otorhinolaryngologica Italica. 2011;31:154
76. DeFatta  RA,   DeFatta  RJ,   Sataloff      Laryngeal   lipotransfer:   Review   of   a   14-year experience. Journal of Voice. 2013;27:512-515
77. Sataloff    Autologous  fat   implantation  for  vocal  fold   scar.   Current  opinion  in otolaryngology & head and neck surgery. 2010;18:503-506

78. Cantarella G, Mazzola RF, Mantovani M, Baracca G, Pignataro Treatment of velopharyngeal insufficiency by pharyngeal and velar fat injections. Otolaryngology– Head and Neck Surgery. 2011;145:401-403
79. Papa N, Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell transplantation. 2014

80. Hovius SE, Kan HJ, Smit X, Selles RW, Cardoso E,  Khouri    Extensive  percutaneous aponeurotomy and lipografting: A new treatment for dupuytren disease. Plastic and reconstructive surgery. 2011;128:221-228
81. Verhoekx JS, Mudera V, Walbeehm ET, Hovius Adipose-derived stem cells inhibit the contractile myofibroblast in  dupuytren’s  disease.  Plastic  and  reconstructive  surgery. 2013;132:1139-1148

82. Bank J, Fuller SM, Henry GI, Zachary Fat grafting to the hand in patients with raynaud phenomenon: A  novel   therapeutic   modality.   Plastic   and   reconstructive   surgery. 2014;133:1109-1118
83. Damgaard OE, Siemssen Lipografted tenolysis. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2010;63:e637-e638
84. Colonna M,   Scarcella   M,   d’Alcontres   F,   Delia   G,   Lupo      Should   fat   graft   be recommended in tendon scar treatment? Considerations on three cases (two feet and a severe burned hand). European review  for  medical  and  pharmacological  sciences. 2014;18:753-759
85. Merikanto JE, Alhopuro S, Ritsilä Free fat transplant prevents osseous reunion of skull defects: A new approach in the treatment of craniosynostosis. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery. 1987;21:183-188
86. Mojallal A,   Lequeux  C,  Shipkov  C,  Breton  P,  Foyatier  J-L,  Braye  F,  Damour   Improvement  of skin quality after  fat  grafting: Clinical observation and  an  animal  study. Plastic and reconstructive surgery. 2009;124:765-774
87. Lockwood  Superficial  fascial  system  (sfs)  of  the  trunk  and  extremities:  A  new concept. Plastic and reconstructive surgery. 1991;87:1009-1018

88. Song AY, Askari M, Azemi E, Alber S, Hurwitz DJ, Marra KG, Shestak KC, Debski R, Rubin Biomechanical properties of the superficial fascial system. Aesthetic Surgery Journal. 2006;26:395-403
89. Flynn     The   use   of   decellularized   adipose    tissue    to    provide    an    inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells. Biomaterials. 2010;31:4715-4724
90. Brown BN, Freund JM, Han L, Rubin JP, Reing JE, Jeffries EM, Wolf MT, Tottey S, Barnes CA, Ratner Comparison of three methods for the derivation of a biologic scaffold composed of adipose tissue extracellular matrix. Tissue Engineering Part C: Methods. 2011;17:411-421
91. Wu I, Nahas Z, Kimmerling KA, Rosson GD, Elisseeff An injectable adipose matrix for soft tissue reconstruction. Plastic and reconstructive surgery. 2012;129:1247
92. Omidi E, Fuetterer L, Mousavi SR, Armstrong RC, Flynn LE, Samani Characterization and assessment of hyperelastic and elastic properties of decellularized human adipose tissues. Journal of biomechanics. 2014;47:3657-3663
93. Wang L,  Johnson  JA,  Zhang  Q,  Beahm  Combining  decellularized  human adipose tissue extracellular matrix and adipose-derived stem cells for adipose tissue engineering.  Acta biomaterialia. 2013;9:8921-8931
94. Healy C, Allen Sr The evolution of perforator flap breast reconstruction: Twenty years after the first diep flap. Journal of reconstructive microsurgery. 2014;30:121-125
95. LoTempio MM, Allen Breast reconstruction with sgap and igap flaps. Plastic and reconstructive surgery. 2010;126:393-401
96. Erić M,  Mihić N,  Krivokuća Breast  reconstruction  following  mastectomy; patient’s satisfaction. Acta Chir Belg. 2009;109:159-166
97. Diaz-Flores L, Gutierrez R, Lizartza K, et Behavior of In Situ Human Native Adipose Tissue CD34+ Stromal/Progenitor Cells During Different Stages of Repair. Tissue-Resident CD34+ Stromal Cells as a Source of Myofibroblasts. Anatomical record. 2014.
98. Gil-Ortega M, Garidou L, Barreau C, et Native adipose stromal cells egress from adipose tissue in vivo: evidence during lymph node activation. Stem cells. 2013;31(7):1309-20.

SATURDAY, 01 OCTOBER 2016 / PUBLISHED IN BLOG

Researchers from the Medical University of South Carolina (MUSC) and the University of Pennsylvania have discovered a new methodology for purifying liver cells generated from induced pluripotent stem cells (iPSCs) that could facilitate progress toward an important clinical goal: treating patients with disease-causing liver mutations by transplanting unmutated liver cells derived from their own stem cells.

Background on Liver Cell Generation from iPSCs

Previous attempts to generate liver-like cells from stem cells have yielded heterogeneous cell populations with little similarity to diseased livers in patients.

The Role of the Next Generation Genetic Association Studies Program

The National Heart, Lung, and Blood Institute (NHLBI)’s Next Generation Genetic Association Studies Program (Next Gen) was created to bank stem cell lines sourced from patients in genome-wide association studies (GWAS). The goal of the Next Gen Lipid Conditions sub-section, a collaborative effort between Stephen A. Duncan, Ph.D., chair of regenerative medicine at MUSC, and Daniel J. Rader, M.D., and Edward E. Morrisey, Ph.D., both at the University of Pennsylvania, is to help determine the genetic sources of heart, lung, or blood conditions that also include the liver.

Genome-Wide Association Studies (GWAS)

GWAS studies map the genomes in hundreds of people to look for genetic mutation patterns that differ from the genomes of healthy individuals. As GWAS studies map more genomes, they become more likely to find the correct genetic mutations that cause a disease. Once a panel of suspected mutations is built, stem cells from these individuals can be manipulated in culture dishes to differentiate into any of the body’s cells. The cells can be screened to learn more about the mutations and to test panels of drugs that might ultimately help treat patients harboring a disease.

Challenges in Cell Manipulation Process

Problems arise during the cell manipulation process. For example, iPSCs persistently refuse to mature uniformly into liver-like cells when fed growth factors. Traditionally, antibodies have been used to recognize features of maturity on the surfaces of cells and purify cells that are similar, an approach that has been crucial to stem cell research. But available antibodies that recognize mature liver cells are scanty and tend to recognize many different kinds of cells. The many types of cells in mixed populations have diverse characteristics that can obscure underlying disease-causing genetic variations, which tend to be subtle.

Introduction of Chemo Proteomic Cell Surface Capture (CSC) Technology

Instead of relying on antibodies, Duncan and his team embraced a new technology called chemo proteomic cell surface capture (CSC) technology. CSC technology allowed the researchers to map the most highly produced proteins on the surface of liver cells during the final stages of differentiation of stem cells into liver cells. The most abundant protein was targeted with an antibody labeled with a fluorescent marker and used to sort the mature liver cells from the rest.

Successful Generation of Pure Liver-like Cells

The procedure was highly successful: The team had a population of highly pure, homogeneous, and mature liver-like cells. Labeled cells had far more similar traits of mature hepatocytes than unlabeled cells. Pluripotent stem cells that had not differentiated were excluded from the group of labeled cells.

“That’s important,” says Duncan. “If you’re wanting to transplant cells into somebody that has liver disease, you really don’t want to be transplanting pluripotent cells because pluripotent cells form tumors called teratocarcinomas.”

Future Implications

Duncan cautioned that transplantation of iPSC-derived liver cells is not yet ready for translation to the clinic, but the technology for sorting homogeneous liver cells can be used now to successfully and accurately model and study disease in the cell culture dish.

“We think that the ability to generate pure populations will get rid of the variability, and therefore really help us combine with GWAS studies to identify allelic variations that are causative of a disease, at least in the liver,” he says.

Contributions to the Study

Researchers at the University of Minnesota (Minneapolis) and the Medical College of Wisconsin (Milwaukee) contributed to the study, published August 25, in Stem Cell Reports.

SATURDAY, 01 OCTOBER 2016 / PUBLISHED IN BLOG

Scientists from the U.K. and Sweden have achieved a significant breakthrough in creating human stem cells that addresses the challenge of large-scale production, unlocking the full potential of stem cells for disease understanding and treatment.

Understanding Human Pluripotent Stem Cells

Human pluripotent stem cells, capable of developing into any type of cell in the body, hold immense promise in disease modeling, drug screening, regenerative medicine, and tissue engineering. The demand for these cells is rapidly increasing in clinical and pharmaceutical settings.

Challenges in Stem Cell Production

Despite their potential, producing stem cells at the necessary scale for research and healthcare applications has been challenging due to expensive culture methods or unsafe substances unsuitable for clinical use.

Breakthrough Methodology

Published in Nature Communications in July, researchers from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling, Uppsala University, and GE Healthcare in Sweden have developed and enhanced human stem cell culture techniques. They have identified a method using Inter-alpha inhibitor, a protein derived from human blood, to grow human pluripotent stem cells in a minimal medium without costly biological substrates.

Advantages of Inter-alpha Inhibitor

Inter-alpha inhibitor, abundant in human blood and a by-product of drug purification, promotes stem cell attachment to unmodified tissue culture plastic. This innovation eliminates the need for coating in defined human pluripotent stem cell culture and enhances cell survival in challenging conditions.

Cost and Efficiency Benefits

This breakthrough method is the first to eliminate the requirement for pre-treated biological substrates, making it more cost-effective and efficient for large-scale production. It holds promise for accelerating high-throughput cultures essential for both basic research and commercial applications.

Future Directions

Future research aims to integrate Inter-alpha inhibitor with advanced hydrogel technologies to further refine cell differentiation control and disease modeling capabilities. The focus includes rare conditions such as Multiple Osteochondroma, aiming to replicate cellular environments accurately for disease modeling.

Research Impact and Recognition

Dr. Sara Pijuan-Galitó, the study’s lead author and a Swedish Research Council Research Fellow at Nottingham, continues to advance this work under the Sir Henry Wellcome Postdoctoral Fellowship. Collaborating with Professor Morgan Alexander and Professor Chris Denning, pioneers in regenerative medicine, the team seeks to develop an economical and safe method for large-scale human stem cell culture.

The study titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture” was published in Nature Communications in July 2016.

MONDAY, 19 SEPTEMBER 2016 / PUBLISHED IN BLOG

Russian researchers have concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells.

Understanding Stem Cells and Reprogramming

Stem cells are specialized, undifferentiated cells with the potential to develop into various cell types in the body. Pluripotent stem cells, capable of generating any cell type, are naturally found in early embryos. They are crucial for internal repair and growth during early life.

Reprogramming Techniques and Their Importance

Reprogramming adult cells involves activating genes typically active in stem cells and deactivating those responsible for cell specialization. This pioneering work by Shinya Yamanaka, Nobel laureate, demonstrated that specific proteins could convert adult cells into pluripotent stem cells, known as induced pluripotent stem cells (iPSCs). This breakthrough avoids ethical concerns associated with using embryonic stem cells.

Potential Applications in Medicine

Stem cells hold promise for treating various diseases. Examples include transplanting retinal pigment epithelium and spinal cells, as well as regenerating teeth in mice. Reprogrammed iPSCs offer a revolutionary approach by allowing personalized treatment using a patient’s own cells.

Scientific Comparison: iPSCs vs. Embryonic Stem Cells

Recent studies have highlighted similarities and differences between iPSCs and embryonic stem cells. Researchers compared isogenic iPSC lines reprogrammed from different adult cell types previously derived from embryonic stem cells. Analysis of transcriptomes and methylated DNA areas showed comparable gene activity regulation mechanisms.

Research Findings and Implications

The study, published in the journal Cell Cycle, concluded that reprogramming adult cells into iPSCs does not leave distinguishing marks compared to embryonic stem cells. Differences observed were attributed to random factors rather than the reprogramming process itself.

“We defined the best induced pluripotent stem cell line concept,” says Dmitry Ischenko, Ph.D., researcher at the Moscow Institute of Physics and Technology.

Future Directions in Stem Cell Research

While this research doesn’t propose organ growth in vitro, it represents a crucial step toward understanding how specialized cells develop from pluripotent cells. Both iPSCs and embryonic stem cells offer potential for generating replacement cells and tissues to treat currently untreatable diseases.

Conclusion

The study, titled “An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion,” involved researchers from the Vavilov Institute of General Genetics, Research Institute of Physical Chemical Medicine, and the Moscow Institute of Physics and Technology (MIPT).

MONDAY, 29 AUGUST 2016 / PUBLISHED IN BLOG

Adult stem cells are gaining significant attention in the scientific community due to their ability to self-renew and generate various types of cells and tissues. Unlike embryonic stem cells, which can differentiate into multiple cell types, adult stem cells primarily produce the specific tissue from which they originate. This focus on adult stem cells has intensified amidst ethical concerns surrounding the use of embryonic stem cells.

Diversity of Adult Stem Cell Sources

Research has identified several adult tissues that harbor stem cells, offering promising avenues for treating degenerative conditions such as osteoarthritis, muscular dystrophy, and Alzheimer’s disease. The expanding list of these tissues includes:

• Bone Marrow: Known for hematopoietic stem cells (HSCs) that can differentiate into blood cells and skeletal stem cells (STCs) contributing to bone and cartilage.
• Brain Tissue: Neural stem cells (NSCs) capable of generating various types of neurons, under study for conditions like multiple sclerosis and Parkinson’s disease.
• Peripheral Blood and Blood Vessel Tissue: Contains hematopoietic stem cells critical for immune function and blood clotting.
• Skeletal Muscle Tissue: Houses muscle stem cells important for muscle repair and regeneration.
• Liver and Pancreas Tissue: Liver’s hepatocytes possess regenerative capabilities, while pancreatic precursor cells from the biliary tree show promise in diabetes research.

Applications in Regenerative Medicine

Adult stem cells offer practical advantages over embryonic stem cells, including lower rejection rates (often sourced from the patient) and higher differentiation potential. This makes them valuable for developing therapies to treat currently incurable diseases in humans.

Future Directions in Stem Cell Research

Scientific advancements continue to uncover new insights into adult stem cells, their capabilities, and potential applications in regenerative medicine. Ongoing research aims to harness these cells’ regenerative properties more effectively, paving the way for novel treatments and therapeutic strategies.

References

For further details, refer to the original research articles and sources:

• MacKlis et al., Nature 2000
• Biliary Tree Stem Cells, Diabetes Research Institute

MONDAY, 29 AUGUST 2016 / PUBLISHED IN BLOG

Recent studies from the Weizmann Institute of Science suggest promising applications of stem cells in repairing damaged lung tissue. This breakthrough offers hope for treating prevalent conditions such as bronchitis, asthma, cystic fibrosis, and emphysema, which collectively affect millions globally and rank among the leading causes of death.

Bone Marrow Stem Cells: Potential for Lung Tissue Regeneration

Researchers at the Weizmann Institute have explored the similarities between lung and bone marrow stem cells. They found that bone marrow stem cells, when transplanted into patients, can migrate through the bloodstream to damaged lung areas and differentiate into lung tissue.

Acknowledging these similarities, Professor Yair Reisner from the Immunology Department conducted experiments where lung stem cell compartments were cleared in mice models before introducing bone marrow stem cells. This approach allowed transplanted stem cells to populate the lungs, differentiate into functional lung tissue, and significantly improve respiratory function over time.

The Weizmann team aims to expand this research to establish a bank of lung-specific stem cells for potential future transplantation in patients with severe respiratory diseases.

Lung-Specific Induced Pluripotent Stem Cells (iPSCs): A Promising Alternative

In parallel research, scientists at the Boston University Medical Center have generated lung-disease-specific induced pluripotent stem cells (iPSCs) from patients with conditions like emphysema and cystic fibrosis. These iPSCs offer advantages over bone marrow stem cells, including easier cultivation and reduced risk of rejection due to genetic similarity to the patient’s own cells.

By manipulating skin stem cells into iPSCs capable of differentiating into lung tissue, researchers have demonstrated their potential in laboratory settings. This approach could circumvent several challenges associated with other stem cell therapies, making it a viable option for future clinical applications.

References

For further reading and detailed studies:

• Chava Rosen et al., Nature Medicine 2015
• Aba Somers et al., Stem Cells 2010